AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1726002
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg of lacidipine once daily (if needed)
Trial: 1726002
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of atenolol once daily (if needed)
Trial: 1726002
Drug: Hydrochlorothiazide (HCTZ,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ, 25 mg once daily) added if required after 2 months
Trial: 6432553
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg bupropion hydrochloride orally with ethanol in orange drink
Trial: 6432553
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg bupropion hydrochloride orally
Trial: 6432553
Drug: dummy tablet
RxNorm normalized name: cholecalciferol / tricalcium phosphate Chewable Tablet [Caltrate Gummy Bites]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dummy tablet
Trial: 10648490
Drug: Atrial overdrive
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial overdrive + propafenone (600 mg/day)
Trial: 8683752
Drug: Desmopressin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin (20 to 40 mcg)
Trial: 7051804
Drug: Early adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early adjuvant chemotherapy (5-fluorouracil, cytoxan, and prednisone)
Trial: 7051804
Drug: Delayed adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed adjuvant chemotherapy (5-fluorouracil, cytoxan, and prednisone)
Trial: 25259737
Drug: Multivitamin and
RxNorm normalized name: Multivitamin and Minerals Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin and mineral preparation (single dose)
Trial: 25259737
Drug: Multivitamin and
RxNorm normalized name: Multivitamin and Minerals Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin and mineral preparation with guaraná (single dose)
Trial: 25552402
Drug: Sublingual asenapine
RxNorm normalized name: asenapine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual asenapine 5 mg after ≥ 10 h fasting (Treatment A, reference)
Trial: 25552402
Drug: Sublingual asenapine
RxNorm normalized name: asenapine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual asenapine 5 mg after a high‐fat meal (Treatment B)
Trial: 25552402
Drug: Sublingual asenapine
RxNorm normalized name: asenapine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual asenapine 5 mg after ≥ 10 h fasting with a high‐fat meal at 4 h post‐dose (Treatment C)
Trial: 25552402
Drug: Sublingual asenapine
RxNorm normalized name: asenapine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual asenapine 5 mg after a high‐fat meal at 4 h post-dose (Treatment C)
Trial: 25552402
Drug: Sublingual asenapine
RxNorm normalized name: asenapine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual asenapine 5 mg after a high‐fat meal (Treatment B) and after ≥ 10 h fasting with a high‐fat meal at 4 h post-dose (Treatment C)
Trial: 17116685
Drug: Three antimalarial
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three antimalarial treatments
Trial: 8506440
Drug: Cilazapril 2.5
RxNorm normalized name: cilazapril 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 2.5 to 5 mg
Trial: 8506440
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 to 100 mg
Trial: 8506440
Drug: Diastolic ambulatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diastolic ambulatory daily values
Trial: 29194927
Drug: Computer guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer guided sinus floor elevation through lateral window approach with simultaneous implant placement
Trial: 29194927
Drug: Standard sinus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard sinus elevation procedure through lateral window approach with simultaneous implant placement
Trial: 27565012
Drug: Acute dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute dose of alcohol (0.8 g/kg)
Trial: 16953457
Drug: Finasteride 1
RxNorm normalized name: finasteride 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride 1 mg co-administered with omeprazole 20 mg
Trial: 8923853
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (constant dose 4 IU/m2 b.s.)
Trial: 3905218
Drug: Diclofenac SR
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac SR 100 mg/day
Trial: 29879602
Drug: Antipsychotic blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic blood levels (ABLs)
Trial: 29879602
Drug: No antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antipsychotic blood levels (ABLs)
Trial: 26444072
Drug: ITI-007 60
RxNorm normalized name: Arthur Itis
DrugBank: Trolamine salicylate (DB11079)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ITI-007 60 mg
Trial: 26444072
Drug: ITI-007 120
RxNorm normalized name: Arthur Itis
DrugBank: Trolamine salicylate (DB11079)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ITI-007 120 mg
Trial: 26444072
Drug: ITI-007 60
RxNorm normalized name: Arthur Itis
DrugBank: Trolamine salicylate (DB11079)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ITI-007 60 mg and 120 mg
Trial: 23743471
Drug: Buccal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buccal misoprostol (400 micrograms)
Trial: 17645503
Drug: Annual screens
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual screens by gynecological examination (sequential pelvic ultrasound [US] and serum CA125 test)
Trial: 9874808
Drug: Celecoxib (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (100, 400, or 800 mg)
Trial: 9874808
Drug: Celecoxib (100-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (100-800 mg)
Trial: 28903767
Drug: Pessary containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pessary containing amphoteric tenside (WO3191) after metronidazole treatment
Trial: 22074122
Drug: Aliskiren 300
RxNorm normalized name: aliskiren 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 300 mg once daily for 24 weeks
Trial: 22074122
Drug: Amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 10 mg once daily for 24 weeks
Trial: 19765769
Drug: Potassium citrate
RxNorm normalized name: Potassium Citrate
DrugBank: Potassium (DB14500)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Potassium citrate (20 mEq) ingested daily by International Space Station crew members
Trial: 2872808
Drug: Terazosin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin with beta blocker plus diuretic
Trial: 2872808
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with beta blocker plus diuretic
Trial: 2872808
Drug: Terazosin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin with other antihypertensive drugs
Trial: 2872808
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with other antihypertensive drugs
Trial: 29081255
Drug: Benda‐14 (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benda‐14 (intravenous bendamustine, 120 mg/m2 on days 1 and 15, repeated every 4 weeks for a total of 6 cycles)
Trial: 18789533
Drug: Distance activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distance activities during 2 hours of daily patching
Trial: 18789533
Drug: Near activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Near activities during 2 hours of daily patching
Trial: 18789533
Drug: 2 hours
RxNorm normalized name: PATCH, TRANSDERMAL 72 HOURS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 hours of daily patching (for children with severe amblyopia)
Trial: 9180977
Drug: Oral ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ondansetron (4 mg) administered 1 hour before induction and additional doses at 8 and 16 hours later
Trial: 9180977
Drug: Oral metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metoclopramide (5 mg) administered under the same conditions
Trial: 15688822
Drug: Adjuvant intraperitoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant intraperitoneal chemotherapy with 50 mg of cisplatinum for washing the peritoneal cavity and 20 mg/m2 of cisplatinum intraperitoneally for the first four days after surgery.
Trial: 15688822
Drug: Adjuvant intraperitoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant intraperitoneal chemotherapy.
Trial: 7863464
Drug: Cloricromene (100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cloricromene (100mg gastroresistant capsules twice a day for 7 days)
Trial: 406300
Drug: Intranasal cromolyn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal cromolyn sodium solution (4% solution, 5.2 mg into each nostril 6 times daily)
Trial: 31519202
Drug: Analysis of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analysis of POST treatment means method
Trial: 25648379
Drug: Nitrous oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrous oxide anesthesia (2 L/min nitrous oxide and 1 L/min oxygen)
Trial: 25648379
Drug: Nitrous oxide-free
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrous oxide-free anesthesia (2 L/min air and 1 L/min oxygen)
Trial: 19659979
Drug: Thalidomide at
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide at a dose of 300 mg/day for 1 week, gradually reduced thereafter.
Trial: 19659979
Drug: Prednisolone 40
RxNorm normalized name: prednisolone 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 40 mg daily for 2 weeks, tapered by 10 mg every 2 weeks.
Trial: 15307695
Drug: Qilian decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qilian decoction (QLD) given orally, one dose taken twice a day
Trial: 15307695
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (hypoglycemic agent in routine)
Trial: 9280714
Drug: Celiprolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol (200 mg/d)
Trial: 9280714
Drug: Ramipril (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (2.5 mg/d)
Trial: 8343915
Drug: 5% EMLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% EMLA cream (25 mg/mL of lidocaine and prilocaine)
Trial: 2883575
Drug: enalapril (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril (2.5 to 40 mg per day)
Trial: 31925970
Drug: Human disease
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human disease network (HDN) analysis of disease treatment cost
Trial: 31231923
Drug: Topical capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical capsaicin (Zostrix HP 0.075%) only (CAP)
Trial: 31231923
Drug: Topical capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical capsaicin with preheating (CAP + HEAT)
Trial: 31231923
Drug: Topical nonsensitizing
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical nonsensitizing placebo cream (CON)
Trial: 26323444
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine (CHX) digluconate and 0.05% cetylpyridinium chloride (CPC) solution
Trial: 23518704
Drug: Drain antisepsis
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drain antisepsis (chlorhexidine disc at drain exit site and irrigation with dilute sodium hypochlorite solution)
Trial: 23518704
Drug: Standard drain
RxNorm normalized name: Standard Drainable Pouch One Piece
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard drain care (twice daily cleansing with alcohol swabs)
Trial: 19252449
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration salt solutions containing rice
Trial: 19252449
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration salt solutions containing amylase-resistant starch
Trial: 19252449
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration salt solutions containing glucose
Trial: 9450156
Drug: pivagabine, 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pivagabine, 900 mg/d for 90 days
Trial: 28671856
Drug: Investigator's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice chemotherapy (ICC; dacarbazine 1,000 mg/m2 every 3 weeks or carboplatin AUC 6 plus paclitaxel 175 mg/m2 every 3 weeks)
Trial: 28671856
Drug: Investigator's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice chemotherapy (ICC)
Trial: 27392256
Drug: Internet program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet program 'Lose It' (recording daily calories and physical activity)
Trial: 27392256
Drug: Daily wellness
RxNorm normalized name: AllerLife Sleep Daily Wellness Support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily wellness program (health tips delivered via e-mail)
Trial: 22520532
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group received enhanced in‐hospital counseling, attention to adherence barriers, communication of discharge medications to community pharmacists and physicians, and ongoing assessment of adherence by community pharmacists.
Trial: 18632105
Drug: Methotrexate (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (30 mg/m2 intramuscularly weekly)
Trial: 18632105
Drug: Actinomycin D
RxNorm normalized name: Actinomycin D
DrugBank: Dactinomycin (DB00970)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Actinomycin D (1.25 mg/m2 intravenous bolus every 2 weeks)
Trial: 16837736
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate (TU) 750 mg
Trial: 24355040
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate (TU) 1000 mg
Trial: 16837736
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate (TU) 1000 mg + Norethisterone enanthate (NETE) 200 mg
Trial: 7982257
Drug: Uni-Dur (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uni-Dur (600 mg once daily for 5 doses)
Trial: 7982257
Drug: Theo-Dur (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theo-Dur (300 mg twice daily for 10 doses)
Trial: 3276446
Drug: Intravenous immunoglobulins
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulins (IVIG) in association with antibiotics
Trial: 31724353
Drug: SU Jia-fu's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SU Jia-fu's Wenjing Tongdu external treatment combined with long-snake moxibustion at the governor vessel, twice a week for 8 weeks.
Trial: 23818201
Drug: Gastrosis No.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastrosis No.1 compound (Chinese herbal medicine)
Trial: 19797813
Drug: Sago gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sago gel (SG)
Trial: 15137922
Drug: 3R,3'R-zeaxanthin dipalmitate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3R,3'R-zeaxanthin dipalmitate (5 mg)
Trial: 15137922
Drug: non-esterified 3R,3'R-zeaxanthin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-esterified 3R,3'R-zeaxanthin (5 mg)
Trial: 8093139
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg fluvastatin
Trial: 8093139
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg fluvastatin
Trial: 8093139
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg fluvastatin plus 8 g cholestyramine
Trial: 8093139
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg fluvastatin plus 8 g cholestyramine
Trial: 8093139
Drug: 16 g
RxNorm normalized name: Maltsupex, 16 g/15 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 g cholestyramine in combination groups
Trial: 25975733
Drug: Basic bladder
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic bladder advice for 1 month followed by alarm therapy (group A)
Trial: 25975733
Drug: Alarm therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alarm therapy only (group B)
Trial: 23139373
Drug: Taspoglutide 10
RxNorm normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taspoglutide 10 mg weekly
Trial: 23139373
Drug: Taspoglutide 20
RxNorm normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taspoglutide 20 mg weekly
Trial: 19130937
Drug: SQ-standardized grass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ-standardized grass allergen tablet (Grazax)
Trial: 16469980
Drug: Butter high
RxNorm normalized name: Cocoa Butter
DrugBank: Cocoa butter (DB11086)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butter high in vaccenic acid (3.6 g vaccenic acid/d)
Trial: 7759830
Drug: Piperacillin 4
RxNorm normalized name: piperacillin 4000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin 4 g intravenously (group P)
Trial: 7759830
Drug: Piperacillin 4
RxNorm normalized name: piperacillin 4000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin 4 g with sulbactam 2 g intravenously (group SP)
Trial: 80579
Drug: Naloxone (as
RxNorm normalized name: Naloxone (as naloxone hydrochloride) 1.8 mg/actuation nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (as second drug)
Trial: 28185713
Drug: Low-dose pitavastatin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose pitavastatin (2 mg/d)
Trial: 23093223
Drug: D-serine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-serine (30 mg/kg) + CRT (5 h/week)
Trial: 22118312
Drug: Topical cromolyn
RxNorm normalized name: cromolyn Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cromolyn sodium 2% ophthalmic solution without 0.01% benzalkonium chloride (BAK)
Trial: 22118312
Drug: Topical cromolyn
RxNorm normalized name: cromolyn Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cromolyn sodium 2% ophthalmic solution with 0.01% benzalkonium chloride (BAK)
Trial: 19189907
Drug: Nurse discharge
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse discharge advocate intervention with follow-up appointments, medication reconciliation, and patient education
Trial: 8404943
Drug: Taprostene (6.25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taprostene (6.25, 12.5, or 25.0 ng.kg‐1 x min‐1) infused for 48 hours followed by a 24-hour tapering period.
Trial: 8404943
Drug: Placebo infused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infused for 48 hours followed by a 24-hour tapering period.
Trial: 31099402
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg every 2 weeks + topical corticosteroids (TCS)
Trial: 31099402
Drug: Cyclosporine +
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine + topical corticosteroids (TCS)
Trial: 21565530
Drug: Dexamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (8 mg at the induction of anesthesia and at the initiation of CPB)
Trial: 14656250
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg vitamin B12
Trial: 14656250
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL saline placebo
Trial: 11429358
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg IV nalbuphine (n = 91)
Trial: 11429358
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg IV propofol (n = 90)
Trial: 7998585
Drug: Rilmenidine 1
RxNorm normalized name: rilmenidine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilmenidine 1 mg orally daily (Group 1)
Trial: 7998585
Drug: Rilmenidine 1
RxNorm normalized name: rilmenidine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilmenidine 1 mg every other day (Group 2)